Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
Joost W. J. van Esser(Amphia Ziekenhuis), Jan J. Cornelissen(Erasmus MC)
Cited by 401
Related Papers
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
|Bone Marrow Transplantation|2020|202
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT
|Journal of Hematology & Oncology|2020|117
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
|Blood|2014|74